Our vision is a world where every cancer patient receives the right therapy.
Our mission is to help the advancement of cancer precision medicine.
We empower healthcare providers with CE/IVD-certified solutions from the tissue handling to the data analysis step of the diagnostic process.
CE-IVD software for analyses of sequencing data from tumors to guide the use of targeted cancer therapies and immuno-checkpoint inhibitors
Fully automated CE-IVD extraction solutions for DNA and RNA without manual reagent handling
Helping our customers to set their workflows for sample isolation and data analysis
Oncodia is an innovative Medical Technology company based in Uppsala, Sweden. We are committed to providing in vitro diagnostic products that consistently meet customer needs, enhance patient treatment outcomes and adhere to regulatory and statutory requirements. Oncodia provides CE/IVD software for precision cancer medicine as well as CE/IVD products for DNA/RNA isolation from diagnostic tissue specimens. Our focus is to supply clinical pathology and oncology with the right solutions for optimal molecular diagnostics of solid tumors.
Oncodia has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 876876
In November 2023, Oncodia secured another round of financing of SEK 6.56M from existing shareholders to further proceed with an updated business strategy combining the
Oncodia has the pleasure to announce the release of the best VARify to date; the CE marked IVD medical device software for tumor-normal mutation analysis.
Dear Customers, We are a proud exhibitor at the Nordic Precision Medicine Forum, which is taking place on the 28th-29th of April in Stockholm, Sweden.
Improving the use of advanced cancer drugs by providing healthcare systems with solutions for highly accurate mutation detection.